Cannabis Law Report

DECEMBER 2, 2021

The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021. Over 70% of these patients face one or more debilitating symptoms, including anxiety, depression, and agitation (Mendez, 2021).

Clinical Trials 52

Clinical Trials Data Patients THC 52

Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. Systematic review and meta-analysis were performed to examine the efficacy and safety of MCs treatment among children.

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

JUNE 23, 2021

Sapphire Medical Clinics presented six abstracts focused on the latest research on cannabinoids based on data from the UK Medical Cannabis Registry during the 31st Annual International Cannabinoid Research Society Symposium on the Cannabinoids (ICRS2021). Patient-reported outcomes. PROGRAMME.and.ABSTRACTS. Improved quality of life.

Cannabinoids 59

Cannabinoids Data Chronic Pain Sleep 59

Cannabis Law Report

DECEMBER 11, 2021

The UK’s first and highest-rated medical cannabis clinic, Sapphire Medical Clinics , has today announced that it is reducing the cost of its consultations and appointments for patients enrolled through the Sapphire Access Scheme. The Sapphire Access Scheme will be open to an additional 2,000 patients in the UK.

Access 52

Access Patients Chronic Pain Treatment 52

Cannabis Law Report

JULY 7, 2021

New data shows MYMD-1 has key differentiators and capabilities compared to existing TNF inhibitor drugs. Data also demonstrated that none of the biological drugs selected for the comparison study proved to be anti-proliferative to any of the primary cell types assessed. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.

Pharmaceutical 105

Pharmaceutical Data Clinical Trials Research and Development 105

Cannabis Law Report

JUNE 7, 2021

The Data and Safety Monitoring Committee (“DSMC”) for IGC’s clinical trial, having reviewed the data obtained through Cohort 1 and Cohort 2, recommended progressing to Cohort 3, which consists of administering three doses per day. This Phase 1 trial is currently testing IGC-AD1 for safety.

Clinical Trials 105

Clinical Trials Patients THC Safety 105

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Veriheal

AUGUST 12, 2021

Patients who suffer from epilepsy , which affects some 3.4 Pharmaceutical CBD is currently a restricted prescription medication, and insurance coverage is often limited to only those patients with the specific approved indications. Researchers Analyzed Survey Results from 280 Epilepsy Patients.

Epilepsy 58

Epilepsy Pharmaceutical Patients Sleep 58

MMJ Recs

NOVEMBER 17, 2023

This article explores the profound impact of MMJ on Maryland communities, shedding light on the medical marijuana benefits experienced by patients and the positive effects it has had on the state’s communities. It has improved the quality of life for those dealing with chronic pain, nausea, seizures, and other medical conditions.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

TheAnswerPage

JANUARY 11, 2022

Are you able to answer your patients’ medical marijuana questions? and ‘The Perioperative Considerations for the Patient Utilizing Cannabinoid-based Medicines and Products.’ million medical marijuana patients nationwide. Written by Dr. Meredith Fisher-Corn, MD , Editor-in-Chief at TheAnswerPage.com.

Patients 98

Patients Education Marijuana Therapy 98

Veriheal

MAY 30, 2023

A new 2023 study published in BMJ Supportive & Palliative Care suggests that cannabis could be the answer millions of cancer patients have been looking for. of patients experience pain after curative treatment, while 66.4% of patients with advanced or metastatic cancer suffer from pain. Interestingly, 72.5%

Medicine 96

Medicine Treatment Patients Data 96

Cannabis Law Report

JUNE 19, 2022

Beckley Psytech aims to track and improve patient experience through an integrated, digitally-assisted treatment model. This latest partnership further strengthens Beckley Psytech’s digital strategy to develop personalised, end-to-end treatment programmes for patients in areas of significant unmet medical need.

Clinical Trials 52

Clinical Trials Patients Research and Development Treatment 52

Cannabis Law Report

JUNE 1, 2021

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. billion, servicing nearly 340,000 active patients.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

Veriheal

NOVEMBER 21, 2023

Quemarr’s transformative approach to diabetes treatment offers patients a less intrusive alternative to conventional insulin treatments. The buddie can be paired with a mobile app that tracks consumption, correlating it with health data from devices like WHOOP, Apple Watch, or Fitbit.

Research and Development 93

Research and Development Consumption Education Data 93

Cannabis Law Report

AUGUST 10, 2021

GW was initially granted marketing authorisation for this medicine in the UK in September 2019 as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older. ADDITIONAL INFORMATION.

Pharmaceutical 98

Pharmaceutical Treatment Epilepsy Research and Development 98

The Joint Blog

MARCH 16, 2020

According to a new study published in the journal Phytotherapy Research, the sustained use of marijuana in patients with chronic conditions is associated with quality of life maintenance and a lack of cognitive decline. Around 90% of participants self-medicated with cannabis daily.

Patients 49

Patients Marijuana Epilepsy Treatment 49

Veriheal

NOVEMBER 18, 2022

Texas’ medical cannabis program is in the midst of a massive spike in patient registrations. According to the Texas Department of Public Safety Chief Wayne Muller, the state has averaged a 10% month-over-month increase in medical cannabis patients over the last 18 months. Let us know in the comments!

Edibles 86

Edibles Hemp Epilepsy Programs 86

MMJ Recs

MARCH 16, 2024

With increasing acceptance of medical marijuana as a legitimate treatment option for various health conditions, the industry has attracted significant attention from investors, entrepreneurs, and policymakers alike. Policy decisions related to taxation, zoning, and advertising also impact the industry’s operations and growth trajectory.

Supply Chain 105

Supply Chain Research and Development Marijuana Seed-To-Sale 105

Cannabis Law Report

JUNE 16, 2021

Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. This engagement will build on the strong foundation on Santé, having treated more than 10,000 patients since 2014 under a real-world data protocol.

Clinical Trials 104

Clinical Trials Therapy Research and Development Events 104

Cannabis Law Report

APRIL 1, 2022

The General Council of Pharmacists has proposed this Monday to carry out a pilot test in pharmacies to assess the use of cannabis for therapeutic purposes, a product that, in the opinion of the president of pharmacists, could have a similar use and conditions of use to those that have other compounds such as morphine.

Medicine 52

Medicine Data Safety Conditions 52

SpeedWeed

MARCH 6, 2021

Public safety at issue. Proponents of these THC caps—who are often the same politicians who stood against legalization and lost—contend that limiting THC levels will increase public safety. Forcing patients to purchase more. Doing so, Pollara wrote, would effectively force a 50% to 150% tax on patients.

THC 52

THC Patients Law Chronic Pain 52

Cannabis Law Report

AUGUST 27, 2021

The Board will advise Delic and its subsidiaries, including Ketamine Infusion Centers, Delic Labs and others, as they develop safety protocols and best practices pertaining to legal psychedelic wellness treatments today and those legalized in the future.

Research and Development 98

Research and Development Treatment Media Medicine 98

Cannabis Law Report

AUGUST 17, 2021

reduction in 28-day seizure frequency relative to baseline in tuberous sclerosis complex (TSC) patients (n=23). reduction was observed in focal seizures (n=19), the most common seizure type in TSC patients. Phase 3 planning for TrustTSC trial ongoing with first patient expected to be enrolled in Q4 2021. Data Highlights.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Veriheal

DECEMBER 23, 2022

Dr. Maxwell’s team also collected data contained in samples sourced from California. After a close analysis of the data, the team determined that an absence of consistent federal guidelines regarding marijuana contaminants ultimately increases the risk of consumers developing health issues.

Research and Development 77

Research and Development Agriculture Data Extraction 77

Veriheal

AUGUST 3, 2021

Under the terms of the legislation, House Bill 1024 will extend cannabis curbside services and indefinitely eradicate the patient cap for actively serving caregivers. In addition to this, patients will be given the opportunity to acquire a 90-day supply of cannabis. Previously, registered patients were limited to a 30-day supply.

Legislation 98

Legislation Patients Supply Chain Dispensary 98

The Cannigma

OCTOBER 21, 2021

Still, many patients report that cannabis helps them to feel more in control of their symptoms, leading to important questions. Attention deficit hyperactivity disorder, or ADHD, is a condition characterized by behavioral symptoms such as inattentiveness, hyperactivity, impulsiveness. Can cannabis help with ADHD? What is ADHD?

Blood Pressure 137

Blood Pressure Treatment Patients Cannabis 137

Veriheal

AUGUST 22, 2022

Based on the details of a June 21 press release, the trials—which are taking place in Johannesburg—are the first ethically approved studies exploring the suitability and safety of using cannabis as a substitute for opioid pain relievers. . ” Dr. S tudy subjects must be willing and ready to substitute opioids with cannabis. “We

Clinical Trials 111

Clinical Trials Chronic Pain Hydroponic Strains 111

Cannabis Law Report

APRIL 12, 2019

I use medical cannabis to treat ankylosing spondylitis and psoriatic arthritis among many other autoimmune conditions, mental health and the effects of chronic inflammation. A patient in Alberta spending $600 (~€397) per month on medical cannabis will pay 24.3% ($145.80) in tax. Patient advocacy is alive and well in Canada.

Access 45

Access Patients Marijuana Medicine 45

The Cannigma

DECEMBER 20, 2021

terpenes ) may help treat a number of different skin conditions. Some of these have been identified as possible targets for the treatment of inflammatory skin conditions. Can cannabis make inflammatory skin conditions worse? The results were very positive and showed the safety and effectiveness of the topical CBD.

Terpenes 133

Terpenes Cannabinoids Topical Research and Development 133

Cannabis Law Report

SEPTEMBER 29, 2021

With more states legalizing cannabis for medical and recreational use, TCI recognizes the critical role that education plays in reducing patient adverse outcomes and ensuring the safe use of cannabis. In addition, Dr. Roberts sees patients at her private practice in Manhattan. TCI was founded by Drs.

Cannabinoids 52

Cannabinoids Education Patients Safety 52

Cannabis Law Report

AUGUST 16, 2021

It is also a tool used to “determine the nature and scope of child abuse and neglect” and compare Arizona data to national trends, regardless of whether that neglect or abuse arose from the lawful or unlawful use of substances, a mental illness or incapacity, or simply an inability to properly care for a child.

Safety 116

Safety Patients Cannabis Law 116

Cannabis Law Report

AUGUST 12, 2021

This regulative environment also promotes economic growth and significant medical benefits, boosting consumer safety and accessibility. In addition, cannabis for medical use will be exported abroad under the same conditions as other addictive substances. This could ultimately lead to a better pharmacy workflow and communication.

Legalization 59

Legalization Pharmaceutical Safety Extraction 59

Cannabis Law Report

OCTOBER 22, 2021

Cybin’s Research and Development team has completed 74 in-vitro and in-vivo evaluations of Cybin’s expanding portfolio of psychedelic compounds being designed for potential therapeutic applications for several mental health conditions.

Research and Development 52

Research and Development Safety Media Data 52

The Cannigma

AUGUST 31, 2021

Barely a quarter of cannabis users trust their doctor to provide them with reliable information about medical cannabis and how to use it to treat their medical or health conditions, according to a recent survey. Physicians will likely be caring for patients who are using cannabis regardless of their own beliefs about it.

Education 101

Education Clinical Trials Medicine Policy 101

Canna Law Blog

DECEMBER 16, 2021

Psilocybin research license, which will allow the testing potency, conducting clinical investigations, researching efficacy and safety, and agricultural research. Expansive List of Qualifying Medical Conditions. Data from the RAND Corporation show that 8,000 New York veterans from the Wars in Iraq and Afghanistan suffer from PTSD.

Legislation 96

Legislation Treatment Therapy Conditions 96

Veriheal

APRIL 11, 2022

You don’t take that opium poppy and ask a patient to rub it on their lip for morphine. We know that the plant has powerful potential medical effects, but it clearly needs more refinement, more research and more data,” stated Groff, who envisions a future where patients can easily access ailment-targeted cannabis meds.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

The Cannigma

JULY 1, 2022

Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. These claims influence things like how consumers purchase cannabis or how doctors consult with medical cannabis patients. Recent data suggest the US science knowledge is about the global average.

Research and Development 108

Research and Development Data THC Clinical Trials 108